Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Ltd is an consolidate pharmaceutical company, focused on providing medicines through its mainly three business segments: Global Generics segment, Pharmaceutical Services and Active Ingredients (PSAI) segment and Proprietary Products segment. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care and biotechnology products.Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.

From 1984-1990 It was incorporated in 1984 by Dr. K. Anji Reddy and has become biggest pharmaceutical company. By 1986, the company prepared to expand still further, and listed its stock on the Bombay exchange, same year company began its first exports of bulk actives, including methyldopa. The company achieved another crucial milestone in 1987 when it gained U.S. FDA approval for its ibuprofen formulation.1988 In order to expand the bulk activities business company acquire Benzex Laboratories. In 1990 For the first time in India norfloxacin and ciprofloxacin was exported to europe.
From 1991-1995
In 1991 First export to Russia and operations start in the city of Moscow. In 1993 Dr. Reddy’s becomes the first company to start work on drug discovery programs in the country. In 1994 Started unit at Bachupally, Hyderabad for finished dosages facility.
From 1997-2000
In 1997 The company successfully completed laboratory testing on the drug, an insulin sensitizer dubbed balaglitazone.Yet, lacking the funds to engage in its own clinical testing, the company placed the patent up for grabs, and licensed it to Novo Nordisk in 1997. The following year, Novo Nordisk acquired the license for Dr. Reddy's second insulin sensitizer, ragaglitazar. In 1999 Acquired American Remedies Limited, based in Chennai, for boosting its formulations capacity. In 2000 After the merger of Cheminor Drugs Limited, Dr. reddy’s laboratories becomes India's third largest pharmaceutical company.
From 2001-2009
In 2001 company lists shared by New York Stock Exchange; a new research and development facility opens in Atlanta, Georgia. In 2002 The company acquires BMS Laboratories Ltd. and its marketing and distribution subsidiary Meridian Healthcare Ltd. in the United Kingdom. In 2003 first generic product launched to be marketed under the “Dr. Reddy’s” label in the US is Ibuprofen. In 2005-2006 Acquires ROCHE’s API Plant in Mexico and fourth largest company in germany- Betapharm In 2007 Launched world’s first biosimilar of a monoclonal antibody-Reditux™ (Rituximab). In 2008 acquisition of Dowpharma’s small molecule business in UK. In 2009 Announces Strategic Alliance with GlaxoSmithKline for emerging markets.